Patient selection is therefore of utmost importance to limit the use of these inhibitors to individuals who are predicted to be hypersensitive to ATR/Chk1 inhibition by virtue of their CLL genetic vulnerability that involves different genetic causes of replication stress. Here, CHEK1 is linked to B-cell chronic lymphocytic leukemia.